Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Optimizing tactics for use of the U.S. Antiviral Strategic National Stockpile for Pandemic (H1N1) Influenza, 2009.

Dimitrov N, Goll S, Hupert N, Pourbohloul B, Meyers LA.

PLoS Curr. 2009 Nov 4;1:RRN1127.

2.

Optimizing tactics for use of the U.S. antiviral strategic national stockpile for pandemic influenza.

Dimitrov NB, Goll S, Hupert N, Pourbohloul B, Meyers LA.

PLoS One. 2011 Jan 19;6(1):e16094. doi: 10.1371/journal.pone.0016094. Erratum in: PLoS One. 2011;6(3). doi: 10.1371/annotation/cf0572ee-8088-4bcc-8680-e8ebb4f05ce3.

3.

Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty.

Greer AL, Schanzer D.

PLoS One. 2013 Jun 21;8(6):e67253. doi: 10.1371/journal.pone.0067253. Print 2013.

4.

Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.

Prosper O, Saucedo O, Thompson D, Torres-Garcia G, Wang X, Castillo-Chavez C.

Math Biosci Eng. 2011 Jan;8(1):141-70. doi: 10.3934/mbe.2011.8.141.

PMID:
21361405
5.

Analysis of the effectiveness of interventions used during the 2009 A/H1N1 influenza pandemic.

Halder N, Kelso JK, Milne GJ.

BMC Public Health. 2010 Mar 29;10:168. doi: 10.1186/1471-2458-10-168.

6.

Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.

McVernon J, McCaw JM, Nolan TM.

Aust N Z J Public Health. 2010 Apr;34(2):113-9. doi: 10.1111/j.1753-6405.2010.00493.x.

PMID:
23331352
7.
8.

Public health management of antiviral drugs during the 2009 H1N1 influenza pandemic: a survey of local health departments in California.

Hunter JC, Rodríguez DC, Aragón TJ.

BMC Public Health. 2012 Jan 25;12:82. doi: 10.1186/1471-2458-12-82.

9.

Optimal H1N1 vaccination strategies based on self-interest versus group interest.

Shim E, Meyers LA, Galvani AP.

BMC Public Health. 2011 Feb 25;11 Suppl 1:S4. doi: 10.1186/1471-2458-11-S1-S4.

10.

Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico.

Chowell G, Viboud C, Simonsen L, Miller MA, Echevarría-Zuno S, González-León M, Aburto VH.

BMC Infect Dis. 2012 Apr 20;12:97.

11.

Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico.

Chowell G, Echevarría-Zuno S, Viboud C, Simonsen L, Tamerius J, Miller MA, Borja-Aburto VH.

PLoS Med. 2011 May;8(5):e1000436. doi: 10.1371/journal.pmed.1000436. Epub 2011 May 24.

12.

Likely effectiveness of pharmaceutical and non-pharmaceutical interventions for mitigating influenza virus transmission in Mongolia.

Bolton KJ, McCaw JM, Moss R, Morris RS, Wang S, Burma A, Darma B, Narangerel D, Nymadawa P, McVernon J.

Bull World Health Organ. 2012 Apr 1;90(4):264-71. doi: 10.2471/BLT.11.093419.

13.

Stockpiling antiviral drugs for the next influenza pandemic.

Patel A, Gorman SE.

Clin Pharmacol Ther. 2009 Sep;86(3):241-3. doi: 10.1038/clpt.2009.142.

PMID:
19707215
14.

Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico.

Gutiérrez-Mendoza LM, Schwartz B, Méndez de Lira Jde J, Wirtz VJ.

Bull World Health Organ. 2012 Oct 1;90(10):782-7. doi: 10.2471/BLT.11.101733. Epub 2012 Aug 17.

15.

Age-prioritized use of antivirals during an influenza pandemic.

Merler S, Ajelli M, Rizzo C.

BMC Infect Dis. 2009 Jul 28;9:117. doi: 10.1186/1471-2334-9-117.

17.

Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.

Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S.

PLoS Med. 2009 May 19;6(5):e1000085. doi: 10.1371/journal.pmed.1000085. Epub 2009 May 19.

18.
19.

Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.

Khazeni N, Hutton DW, Garber AM, Owens DK.

Ann Intern Med. 2009 Dec 15;151(12):840-53. doi: 10.7326/0003-4819-151-12-200912150-00156.

20.

Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance.

Davey VJ, Glass RJ, Min HJ, Beyeler WE, Glass LM.

PLoS One. 2008 Jul 2;3(7):e2606. doi: 10.1371/journal.pone.0002606.

Supplemental Content

Support Center